Macrogenics Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $175.1M+16.8% YoYTTM through 30 Jun 2026
Net Income -$14.6MTTM through 30 Jun 2026
Free Cash Flow -$65.5MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| EBITDA Margin | -18.4% |
| Operating Margin | -161.1% |
| Net Margin | -8.3% |
Returns
-173.5%ROE
-18.0%ROA
Balance Sheet Health
Debt / Equity3.24x
Current Ratio1.90x
Net Debt-$154.2Mnet cash position
Cash & Equivalents$113.9M
Quality Metrics
Altman Z-Score-3.71
Piotroski F-Score2 / 9
FCF Margin-37.4%
Earnings-Beat Rate25.0%
Multi-Year Trend
RevenueFY2025: $149.5M
Diluted EPS-$0.22TTMFY2025: $-1.18
Dividend
No dividend
Capital Allocation
R&D Spend$140.4M
Capex Intensity1.0%
Segment Performance
No segment data available.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.